ArticleEuropean psychiatry : the journal of the Association of European Psychiatrists2025
Investigating the association between GLP-1 receptor agonists and mood disorders: A study integrating real-world data and Mendelian randomization.
Article in European psychiatry : the journal of the Association of European Psychiatrists, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Suicidality as a potential risk and therapeutic target during widespread GLP-1 receptor agonists use: implications of inflammation.Frontiers in synaptic neuroscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAs GLP-1 receptor agonists (GLP-1 RAs) are increasingly used worldwide, concerns about their association with mood disorders have grown. Yet real-world observational studies have produced conflicting findings. This study aims to fully examine the link between GLP-1 RAs and emotional/behavioral outcomes.
methodsDisproportionality analysis of GLP-1 RA adverse events was conducted using FAERS data. Mendelian randomization (MR) employed GLP1R cis-eQTLs as instrumental variables to assess links with mood/behavior-related disorders. Summary-data MR (SMR) was then performed using GLP1R cis-eQTL data.
results275,718 adverse events (AEs) associated with GLP-1 RAs were retrieved and analyzed. A mild signal for suicide-related AEs was observed only in the obesity indication subgroup (ROR:1.65, 95% CI: 1.28-2.12). Genetic evidence showed that GLP-1 RAs were likely associated with reduced risks of anxiety, depression, emotional lability, bipolar disorder, and suicide. Mediational analysis indicated that weight loss partially mediated the causal effects of GLP-1 RAs on depression and emotional lability, accounting for 18.28% (95% CI: 9.46-27.10%,
conclusionsBoth observational and MR analyses showed that patients treated with GLP-1 RAs may have no increased risk of emotional and behavioral disorders. Instead, genetic proxy activation of GLP-1 RAs may reduce the risk of anxiety, depression, and emotional lability.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.